• Corteva, Inc. reported its fourth-quarter and full-year 2025 results in early February, with quarterly sales easing to US$3,910 million and a net loss of US$552 million, but full-year sales rising to US$17.40 billion and net income reaching US$1.09 billion.
• Alongside record free cash flow of US$2.90 billion, Corteva resolved long-running seed-licensing litigation with Bayer and reaffirmed its plan to spin off the seeds business around late 2026, reshaping its future as a pure-play crop protection company.
• We will now examine how the Bayer legal resolution and seeds spin-off plan influence Corteva’s investment narrative and risk profile.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

What Is Corteva's Investment Narrative?

For Corteva, the investment story now hinges on two moving parts: the path to a pure-play crop protection business and what the Bayer settlement unlocks along the way. The latest results mixed a soft Q4, with a US$552 million loss, against a solid full-year picture and record US$2.90 billion free cash flow, which helps to absorb the US$610 million settlement payment. Management’s 2026 operating EPS guidance of US$3.45 to US$3.70 and confirmation of the dividend and buybacks keep capital return and execution as key short term catalysts. At the same time, the seed spin off timeline, integration of the new Bayer licensing arrangements and relatively high valuation multiples sharpen the risk if margins or growth falter. The recent news intensifies, rather than changes, those core debates.

However, one risk in particular could matter more than it first appears. Corteva's share price has been on the slide but might be up to 10% below fair value. Find out if it's a bargain.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community span roughly US$53 to US$78, underlining how far apart individual views can be. Set against Corteva’s sizeable spin off and Bayer-related restructuring, that spread shows why it is worth weighing several perspectives before deciding how resilient the earnings story really is.

Explore 6 other fair value estimates on Corteva - why the stock might be worth as much as 8% more than the current price!

Build Your Own Corteva Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Corteva research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Corteva research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corteva's overall financial health at a glance.

No Opportunity In Corteva?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Outshine the giants: these 30 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.